Gender differences in HIV drug resistance mutations and virological outcome

Vidya Mave, Mona Gahunia, Maria Frontini, Rebecca Clark, David Mushatt

Research output: Contribution to journalArticle

Abstract

Background: Previous studies have shown that female gender has higher odds of developing HIV drug resistance mutations. We aimed to evaluate the gender differences in HIV drug resistance mutation patterns and outcomes in a cohort of an HIV-infected population who underwent genotype resistance testing (GRT). Methods: We conducted a retrospective study from January 2004 to April 2007 of patients >12 years of age who underwent GRT in the HIV Outpatient Program Clinic (HOP) at the Medical Center of Louisiana at New Orleans. Results: Among 391 patients included in the analysis, 130 were females and 261 were males. There were no major statistically significant differences in the baseline demographic, clinical, or genotypic characteristics between males and females before GRT except for race, presence of coexisting hepatitis B and C infection, prior diagnosis of tuberculosis, presence of thymidine analogue mutations (TAMs), and protease inhibitor (PI) mutations L90M and I84V (p

Original languageEnglish (US)
Pages (from-to)117-122
Number of pages6
JournalJournal of Women's Health
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Drug Resistance
HIV
Mutation
Genotype
Hepatitis C
Ambulatory Care Facilities
Protease Inhibitors
Hepatitis B
Thymidine
Tuberculosis
Retrospective Studies
Demography
Infection
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gender differences in HIV drug resistance mutations and virological outcome. / Mave, Vidya; Gahunia, Mona; Frontini, Maria; Clark, Rebecca; Mushatt, David.

In: Journal of Women's Health, Vol. 20, No. 1, 01.01.2011, p. 117-122.

Research output: Contribution to journalArticle

Mave, Vidya ; Gahunia, Mona ; Frontini, Maria ; Clark, Rebecca ; Mushatt, David. / Gender differences in HIV drug resistance mutations and virological outcome. In: Journal of Women's Health. 2011 ; Vol. 20, No. 1. pp. 117-122.
@article{2afd903cd9d9479e909b6cbf1b7b5314,
title = "Gender differences in HIV drug resistance mutations and virological outcome",
abstract = "Background: Previous studies have shown that female gender has higher odds of developing HIV drug resistance mutations. We aimed to evaluate the gender differences in HIV drug resistance mutation patterns and outcomes in a cohort of an HIV-infected population who underwent genotype resistance testing (GRT). Methods: We conducted a retrospective study from January 2004 to April 2007 of patients >12 years of age who underwent GRT in the HIV Outpatient Program Clinic (HOP) at the Medical Center of Louisiana at New Orleans. Results: Among 391 patients included in the analysis, 130 were females and 261 were males. There were no major statistically significant differences in the baseline demographic, clinical, or genotypic characteristics between males and females before GRT except for race, presence of coexisting hepatitis B and C infection, prior diagnosis of tuberculosis, presence of thymidine analogue mutations (TAMs), and protease inhibitor (PI) mutations L90M and I84V (p",
author = "Vidya Mave and Mona Gahunia and Maria Frontini and Rebecca Clark and David Mushatt",
year = "2011",
month = "1",
day = "1",
doi = "10.1089/jwh.2009.1846",
language = "English (US)",
volume = "20",
pages = "117--122",
journal = "Journal of Women's Health",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Gender differences in HIV drug resistance mutations and virological outcome

AU - Mave, Vidya

AU - Gahunia, Mona

AU - Frontini, Maria

AU - Clark, Rebecca

AU - Mushatt, David

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Previous studies have shown that female gender has higher odds of developing HIV drug resistance mutations. We aimed to evaluate the gender differences in HIV drug resistance mutation patterns and outcomes in a cohort of an HIV-infected population who underwent genotype resistance testing (GRT). Methods: We conducted a retrospective study from January 2004 to April 2007 of patients >12 years of age who underwent GRT in the HIV Outpatient Program Clinic (HOP) at the Medical Center of Louisiana at New Orleans. Results: Among 391 patients included in the analysis, 130 were females and 261 were males. There were no major statistically significant differences in the baseline demographic, clinical, or genotypic characteristics between males and females before GRT except for race, presence of coexisting hepatitis B and C infection, prior diagnosis of tuberculosis, presence of thymidine analogue mutations (TAMs), and protease inhibitor (PI) mutations L90M and I84V (p

AB - Background: Previous studies have shown that female gender has higher odds of developing HIV drug resistance mutations. We aimed to evaluate the gender differences in HIV drug resistance mutation patterns and outcomes in a cohort of an HIV-infected population who underwent genotype resistance testing (GRT). Methods: We conducted a retrospective study from January 2004 to April 2007 of patients >12 years of age who underwent GRT in the HIV Outpatient Program Clinic (HOP) at the Medical Center of Louisiana at New Orleans. Results: Among 391 patients included in the analysis, 130 were females and 261 were males. There were no major statistically significant differences in the baseline demographic, clinical, or genotypic characteristics between males and females before GRT except for race, presence of coexisting hepatitis B and C infection, prior diagnosis of tuberculosis, presence of thymidine analogue mutations (TAMs), and protease inhibitor (PI) mutations L90M and I84V (p

UR - http://www.scopus.com/inward/record.url?scp=79251470450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251470450&partnerID=8YFLogxK

U2 - 10.1089/jwh.2009.1846

DO - 10.1089/jwh.2009.1846

M3 - Article

VL - 20

SP - 117

EP - 122

JO - Journal of Women's Health

JF - Journal of Women's Health

SN - 1540-9996

IS - 1

ER -